vs
Huron Consulting Group Inc.（HURN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Huron Consulting Group Inc.的1.7倍（$772.1M vs $442.0M），Revvity净利率更高（12.7% vs 6.9%，领先5.8%），Huron Consulting Group Inc.同比增速更快（10.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $123.8M），过去两年Huron Consulting Group Inc.的营收复合增速更高（10.3% vs 9.0%）
休伦咨询集团是一家全球专业管理咨询服务提供商，深耕医疗健康、生命科学、商业企业及高等教育四大核心领域，为各行业客户定制适配业务发展的解决方案，助力客户优化运营效率、实现长期发展目标。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HURN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$442.0M
营收增速更快
HURN
高出4.8%
5.9%
净利率更高
RVTY
高出5.8%
6.9%
自由现金流更多
RVTY
多$38.0M
$123.8M
两年增速更快
HURN
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $442.0M | $772.1M |
| 净利润 | $30.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 11.4% | 14.5% |
| 净利率 | 6.9% | 12.7% |
| 营收同比 | 10.7% | 5.9% |
| 净利润同比 | -9.8% | 3.9% |
| 每股收益（稀释后） | $1.71 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HURNRVTY
| Q4 25 | $442.0M | $772.1M | ||
| Q3 25 | $441.3M | $698.9M | ||
| Q2 25 | $411.8M | $720.3M | ||
| Q1 25 | $404.1M | $664.8M | ||
| Q4 24 | $399.3M | $729.4M | ||
| Q3 24 | $378.1M | $684.0M | ||
| Q2 24 | $381.0M | $691.7M | ||
| Q1 24 | $363.4M | $649.9M |
净利润HURNRVTY
| Q4 25 | $30.7M | $98.4M | ||
| Q3 25 | $30.4M | $46.7M | ||
| Q2 25 | $19.4M | $53.9M | ||
| Q1 25 | $24.5M | $42.2M | ||
| Q4 24 | $34.0M | $94.6M | ||
| Q3 24 | $27.1M | $94.4M | ||
| Q2 24 | $37.5M | $55.4M | ||
| Q1 24 | $18.0M | $26.0M |
毛利率HURNRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HURNRVTY
| Q4 25 | 11.4% | 14.5% | ||
| Q3 25 | 11.3% | 11.7% | ||
| Q2 25 | 11.1% | 12.6% | ||
| Q1 25 | 8.1% | 10.9% | ||
| Q4 24 | 11.8% | 16.3% | ||
| Q3 24 | 11.2% | 14.3% | ||
| Q2 24 | 15.6% | 12.4% | ||
| Q1 24 | 5.5% | 6.8% |
净利率HURNRVTY
| Q4 25 | 6.9% | 12.7% | ||
| Q3 25 | 6.9% | 6.7% | ||
| Q2 25 | 4.7% | 7.5% | ||
| Q1 25 | 6.1% | 6.4% | ||
| Q4 24 | 8.5% | 13.0% | ||
| Q3 24 | 7.2% | 13.8% | ||
| Q2 24 | 9.8% | 8.0% | ||
| Q1 24 | 5.0% | 4.0% |
每股收益（稀释后）HURNRVTY
| Q4 25 | $1.71 | $0.86 | ||
| Q3 25 | $1.71 | $0.40 | ||
| Q2 25 | $1.09 | $0.46 | ||
| Q1 25 | $1.33 | $0.35 | ||
| Q4 24 | $1.82 | $0.77 | ||
| Q3 24 | $1.47 | $0.77 | ||
| Q2 24 | $2.03 | $0.45 | ||
| Q1 24 | $0.95 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.5M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $528.6M | $7.3B |
| 总资产 | $1.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HURNRVTY
| Q4 25 | $24.5M | $919.9M | ||
| Q3 25 | $23.9M | $931.4M | ||
| Q2 25 | $61.0M | $991.8M | ||
| Q1 25 | $23.4M | $1.1B | ||
| Q4 24 | $21.9M | $1.2B | ||
| Q3 24 | $18.5M | $1.2B | ||
| Q2 24 | $17.6M | $2.0B | ||
| Q1 24 | $18.6M | $1.7B |
股东权益HURNRVTY
| Q4 25 | $528.6M | $7.3B | ||
| Q3 25 | $499.8M | $7.4B | ||
| Q2 25 | $475.0M | $7.6B | ||
| Q1 25 | $494.3M | $7.6B | ||
| Q4 24 | $561.3M | $7.7B | ||
| Q3 24 | $522.8M | $7.9B | ||
| Q2 24 | $500.6M | $7.9B | ||
| Q1 24 | $495.6M | $7.8B |
总资产HURNRVTY
| Q4 25 | $1.5B | $12.2B | ||
| Q3 25 | $1.5B | $12.1B | ||
| Q2 25 | $1.5B | $12.4B | ||
| Q1 25 | $1.4B | $12.4B | ||
| Q4 24 | $1.3B | $12.4B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $123.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 28.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 4.12× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $183.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HURNRVTY
| Q4 25 | $126.4M | $182.0M | ||
| Q3 25 | $93.8M | $138.5M | ||
| Q2 25 | $80.0M | $134.3M | ||
| Q1 25 | $-106.8M | $128.2M | ||
| Q4 24 | $139.6M | $174.2M | ||
| Q3 24 | $85.2M | $147.9M | ||
| Q2 24 | $107.2M | $158.6M | ||
| Q1 24 | $-130.7M | $147.6M |
自由现金流HURNRVTY
| Q4 25 | $123.8M | $161.8M | ||
| Q3 25 | $89.8M | $120.0M | ||
| Q2 25 | $78.0M | $115.5M | ||
| Q1 25 | $-108.7M | $112.2M | ||
| Q4 24 | $137.0M | $149.8M | ||
| Q3 24 | $82.8M | $125.6M | ||
| Q2 24 | $104.7M | $136.6M | ||
| Q1 24 | $-131.9M | $129.7M |
自由现金流率HURNRVTY
| Q4 25 | 28.0% | 21.0% | ||
| Q3 25 | 20.3% | 17.2% | ||
| Q2 25 | 18.9% | 16.0% | ||
| Q1 25 | -26.9% | 16.9% | ||
| Q4 24 | 34.3% | 20.5% | ||
| Q3 24 | 21.9% | 18.4% | ||
| Q2 24 | 27.5% | 19.7% | ||
| Q1 24 | -36.3% | 20.0% |
资本支出强度HURNRVTY
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 0.7% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% | ||
| Q1 24 | 0.3% | 2.7% |
现金转化率HURNRVTY
| Q4 25 | 4.12× | 1.85× | ||
| Q3 25 | 3.08× | 2.97× | ||
| Q2 25 | 4.12× | 2.49× | ||
| Q1 25 | -4.35× | 3.03× | ||
| Q4 24 | 4.11× | 1.84× | ||
| Q3 24 | 3.14× | 1.57× | ||
| Q2 24 | 2.86× | 2.87× | ||
| Q1 24 | -7.26× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HURN
| Consulting And Managed Services Capability | $172.9M | 39% |
| Education | $118.7M | 27% |
| Commercial | $91.9M | 21% |
| Digital Capability | $54.6M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
